ArticleMolecular cancer therapeutics2025

Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma.

Smita Matkar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.